ATE441430T1 - Faktor viia oder faktor viia äquivaltenen zur prävention oder abschwächung des wachstums von hämorrhagien und/oder der ídemerzeugung nach intrazerebraler hämorrhagie (ich) - Google Patents

Faktor viia oder faktor viia äquivaltenen zur prävention oder abschwächung des wachstums von hämorrhagien und/oder der ídemerzeugung nach intrazerebraler hämorrhagie (ich)

Info

Publication number
ATE441430T1
ATE441430T1 AT05756838T AT05756838T ATE441430T1 AT E441430 T1 ATE441430 T1 AT E441430T1 AT 05756838 T AT05756838 T AT 05756838T AT 05756838 T AT05756838 T AT 05756838T AT E441430 T1 ATE441430 T1 AT E441430T1
Authority
AT
Austria
Prior art keywords
hemorrhagia
factor viia
preventing
intracerebral
attenuation
Prior art date
Application number
AT05756838T
Other languages
English (en)
Inventor
Nikolai Constantin Brun
Elisabeth Erhardtsen
Brett E Skolnick
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Application granted granted Critical
Publication of ATE441430T1 publication Critical patent/ATE441430T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
AT05756838T 2004-06-21 2005-06-21 Faktor viia oder faktor viia äquivaltenen zur prävention oder abschwächung des wachstums von hämorrhagien und/oder der ídemerzeugung nach intrazerebraler hämorrhagie (ich) ATE441430T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200400972 2004-06-21
DKPA200400981 2004-06-23
PCT/EP2005/052890 WO2005123118A1 (en) 2004-06-21 2005-06-21 Use of factor viia or factor viia equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ich)

Publications (1)

Publication Number Publication Date
ATE441430T1 true ATE441430T1 (de) 2009-09-15

Family

ID=35058275

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05756838T ATE441430T1 (de) 2004-06-21 2005-06-21 Faktor viia oder faktor viia äquivaltenen zur prävention oder abschwächung des wachstums von hämorrhagien und/oder der ídemerzeugung nach intrazerebraler hämorrhagie (ich)

Country Status (13)

Country Link
US (2) US20060019894A1 (de)
EP (1) EP1761274B1 (de)
JP (2) JP5523671B2 (de)
KR (1) KR20070027709A (de)
AT (1) ATE441430T1 (de)
AU (1) AU2005253749A1 (de)
BR (1) BRPI0512316A (de)
CA (1) CA2570330A1 (de)
DE (1) DE602005016406D1 (de)
ES (1) ES2331653T3 (de)
MX (1) MXPA06015045A (de)
RU (1) RU2006144397A (de)
WO (1) WO2005123118A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1906993A2 (de) * 2005-07-15 2008-04-09 Novo Nordisk Health Care AG Verwendung von faktor viia oder faktor viia-äquivalenten zur prävention oder abschwächung von hämorrhagiewachstum und/oder ödembildung nach interzerebraler blutung (ich) bei patienten unter einer anti-thrombozyten-therapie
US8252302B2 (en) * 2007-06-11 2012-08-28 Edge Therapeutics, Inc. Methods and compositions to treat hemorrhagic conditions of the brain
CN101918025A (zh) * 2008-01-18 2010-12-15 诺沃-诺迪斯克保健股份有限公司 因子Ⅶa或因子Ⅶa等同物用于防止或减弱选择的脑内出血患者亚群在脑内出血(ICH)后出血增多和/或水肿形成的用途
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
SI3096779T1 (sl) * 2014-01-24 2020-03-31 Pfizer Inc. Sestavki in postopki za zdravljenje intracerebralne krvavitve
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998058661A1 (en) * 1997-06-23 1998-12-30 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
EP1216709A1 (de) * 2000-12-21 2002-06-26 Boehringer Ingelheim Pharma KG Verwendung von aktiviertem Gerinnungsfaktor VII zur Behandlung von durch thrombolytische Therapie-induzierten wichtigen Blutungen
CA2436807A1 (en) * 2001-02-05 2002-08-15 Novo Nordisk Health Care Ag Combined use of factor vii polypeptides and factor viii polypeptides
EP1906993A2 (de) * 2005-07-15 2008-04-09 Novo Nordisk Health Care AG Verwendung von faktor viia oder faktor viia-äquivalenten zur prävention oder abschwächung von hämorrhagiewachstum und/oder ödembildung nach interzerebraler blutung (ich) bei patienten unter einer anti-thrombozyten-therapie

Also Published As

Publication number Publication date
DE602005016406D1 (de) 2009-10-15
US20060019894A1 (en) 2006-01-26
JP5523671B2 (ja) 2014-06-18
US20070243183A1 (en) 2007-10-18
ES2331653T3 (es) 2010-01-12
EP1761274A1 (de) 2007-03-14
RU2006144397A (ru) 2008-07-27
BRPI0512316A (pt) 2008-02-26
EP1761274B1 (de) 2009-09-02
JP2008503543A (ja) 2008-02-07
JP2012197279A (ja) 2012-10-18
WO2005123118A1 (en) 2005-12-29
AU2005253749A1 (en) 2005-12-29
KR20070027709A (ko) 2007-03-09
CA2570330A1 (en) 2005-12-29
MXPA06015045A (es) 2007-03-21

Similar Documents

Publication Publication Date Title
TW200716145A (en) Use of LGG in the manufacture of a medicament for the prevention or treatment of respiratory allergies
ATE551063T1 (de) Verwendung von bifidobacterium longum zur prophylaxe und behandlung von entzündungen
HK1124546A1 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
ATE447948T1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von schmerzen
ATE376828T1 (de) Verwendung von rotigotin zur behandlung und prävention des parkinson-plus-syndroms
UA98125C2 (ru) Замещенные дигидропиразолоны для лечения сердечно-сосудистых и гематологических заболеваний
ATE441430T1 (de) Faktor viia oder faktor viia äquivaltenen zur prävention oder abschwächung des wachstums von hämorrhagien und/oder der ídemerzeugung nach intrazerebraler hämorrhagie (ich)
ATE464895T1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von depressionen
WO2009079451A3 (en) Compositions and methods of promoting wound healing
DE602005026276D1 (de) Myricitrin verbindungen zur behandlung von schlafstörungen
TNSN07263A1 (en) Substituted 4-phenyl tetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them
TW200724146A (en) Use of LGG in the manufacture of a medicament for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
ATE526967T1 (de) Medikamente für inhalationen enthaltend ein anticholinergikum und ein betamimetikum
MXPA05001885A (es) El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica.
DE60115054D1 (de) Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs
ATE479423T1 (de) Vorrichtung für die topische anwendung des medizinischen ozons zur behandlung von erkrankungen der mundhöhle
ATE431741T1 (de) Marrubin und zusammensetzung zur verringerung von schnarchen, verpackung und verfahren
WO2006076014A3 (en) Interferon-alpha constructs for use in the treatment of sars
DE602006020838D1 (de) Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum
EA201070193A1 (ru) Лечение детских опухолей
DE502004010212D1 (de) Verwendung von tyrosinkinase-inhibitoren zur behandlung inflammatorischer prozesse
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
EA200601853A1 (ru) Лечение нарушенной дыхательной функции
TW200633705A (en) Treatment of macular degeneration with lonidamine
MX2008011312A (es) Analogos de meridamicina para el tratamiento de trastornos neurodegenerativos.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties